Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
127.60    2.60 (2.08%)
Bid:
127.60
Ask:
128.40
Spread: 0.80 (0.627%)
Market Cap: £310.60m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Director/PDMR Shareholding

13 Nov 2020 17:00

RNS Number : 3174F
PureTech Health PLC
13 November 2020
 

PureTech Health plc (the "Company")

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility or their Connected Persons

 

In connection with the listing of the Company's American Depository Shares ("ADS's") on the Nasdaq Global Market and in order to satisfy Nasdaq listing rules, on 11 November 2020, (i) the Zohar Family Trust I, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to per one ADS and (ii) the Zohar Family Trust II, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to one ADS.

 

The foregoing is a notifiable transaction but does not involve any disposal of such interest. Following this transaction, Ms. Zohar continues to have a direct and indirect interest in 12,197,307 Ordinary Shares, representing approximately 4.3% of the issued share capital of the Company. No Ordinary Shares or ADS's are being sold or disposed of by Ms. Zohar or her related entities in connection with the Nasdaq listing.

 

This notification is made under Article 19 of the Market Abuse Regulation.

 

PDMR DEALING NOTIFICATION

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

The Zohar Family Trust I and The Zohar Family Trust II

2

Reason for the notification

a)

Position/status

Ms. Daphne Zohar, the Chief Executive Officer and a Director, is a Trustee of the above listed Trusts

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

PureTech Health plc

b)

LEI

213800LVPDNO2Z9T9I39

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of PureTech Health plc

ISIN GB00BY2Z0H74

b)

Nature of the transaction

Conversion by the Zohar Family Trust I of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration and conversion by the Zohar Family Trust II of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Zohar Family Trust I

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

Zohar Family Trust II

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

d)

Aggregated information

-

Aggregated volume

-

Price

 

Price

Aggregate Volume

n/a

n/a

e)

Date of the transaction

11 November 2020

f)

Place of the transaction

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZXLFFBFLLFBK
Date   Source Headline
20th Feb 20237:00 amRNSTransaction in Own Shares
17th Feb 20235:00 pmRNSDirector/PDMR Shareholding
17th Feb 20237:00 amRNSTransaction in Own Shares
16th Feb 20237:00 amRNSTransaction in Own Shares
15th Feb 20237:00 amRNSTransaction in Own Shares
14th Feb 202312:00 pmRNSPRTC Plans Ph2a trials w/ LYT-300 in PPD/Anxiety
14th Feb 20237:00 amRNSTransaction in Own Shares
13th Feb 20237:00 amRNSTransaction in Own Shares
10th Feb 20237:00 amRNSTransaction in Own Shares
9th Feb 20237:00 amRNSTransaction in Own Shares
8th Feb 20237:00 amRNSTransaction in Own Shares
7th Feb 20237:00 amRNSTransaction in Own Shares
6th Feb 20237:00 amRNSTransaction in Own Shares
3rd Feb 20237:00 amRNSTransaction in Own Shares
2nd Feb 20237:00 amRNSTransaction in Own Shares
1st Feb 202312:00 pmRNSPureTech to Present at SVB Global Biopharma Conf.
1st Feb 20237:00 amRNSTotal Voting Rights
1st Feb 20237:00 amRNSTransaction in Own Shares
31st Jan 20237:00 amRNSTransaction in Own Shares
30th Jan 20237:00 amRNSTransaction in Own Shares
27th Jan 20237:00 amRNSTransaction in Own Shares
25th Jan 20237:00 amRNSTransaction in Own Shares
6th Jan 20237:00 amRNSAKLI Positive ADHD Pivotal Data in Kids 13-17 yrs
22nd Dec 20227:00 amRNSPRTC Provides Recap Ahead of Catalyst-Rich 2023
19th Dec 202212:00 pmRNSLYT-300 Shows Proof of Principle in Clinical Trial
13th Dec 202212:00 pmRNSPureTech to Present at J.P. Morgan HC Conference
12th Dec 20222:00 pmRNSPRTC Leukemia Data at ASH & Begins AML Trial
9th Dec 202212:00 pmRNSSonde Gets $19M+ for Voice-Based Health Monitoring
7th Dec 20222:13 pmRNSVor Announces AML Clinical Data + Raises $115M
6th Dec 20226:30 pmRNSDirector/PDMR Shareholding
1st Dec 20227:00 amRNSTotal Voting Rights
30th Nov 202212:00 pmRNSPRTC's New Candidate: Oral CBD for Epilepsy/CNS
22nd Nov 20227:00 amRNSTransaction in Own Shares
21st Nov 20227:00 amRNSTransaction in Own Shares
18th Nov 20227:00 amRNSTransaction in Own Shares
17th Nov 202212:00 pmRNSPRTC Presents at Two Upcoming Investor Conferences
17th Nov 20227:00 amRNSTransaction in Own Shares
16th Nov 20227:00 amRNSTransaction in Own Shares
15th Nov 20227:00 amRNSTransaction in Own Shares
14th Nov 20227:00 amRNSTransaction in Own Shares
11th Nov 20227:00 amRNSTransaction in Own Shares
10th Nov 20225:00 pmRNSDirector Declaration
10th Nov 20227:00 amRNSTransaction in Own Shares
9th Nov 202212:00 pmRNSPRTC to Present at Jefferies Healthcare Conference
9th Nov 20227:00 amRNSTransaction in Own Shares
8th Nov 20227:00 amRNSTransaction in Own Shares
7th Nov 20227:00 amRNSTransaction in Own Shares
4th Nov 20227:00 amRNSTransaction in Own Shares
3rd Nov 20227:00 amRNSTransaction in Own Shares
2nd Nov 202211:35 amRNSGelesis Presents New Data at ObesityWeek 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.